Navigation Links
Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
Date:2/1/2012

RICHMOND, Calif., Feb. 1, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its fourth quarter and full year 2011 financial results on Wednesday, February 8, 2012, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 46071015.  Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations" http://investor.sangamo.com/events.cfm. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on February 8, 2012 to midnight ET on February 15, 2011. The conference call replay numbers for domestic and international callers are 855-859-2056 and 404-537-3406 respectively. The conference ID number for the replay is 46071015.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. Sangamo has a Phase 2 clinical trial and two Phase 1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS.  Other therapeutic programs are focused on monogenic diseases, including hemophilia and hemoglobinopathies, and Parkinson's disease. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding prote
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
2. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
3. Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
5. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
6. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
7. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
8. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
9. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
10. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
11. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... BOULDER, Colo. , Jan. 23, 2015  Array BioPharma ... it has reached a definitive agreement with Novartis Pharma ... BRAF inhibitor currently in Phase 3 development.  This agreement is ... and GlaxoSmithKline PLC (GSK) on April 22, 2014, which are ...
(Date:1/22/2015)... 2015 GEA Niro Soavi the leader ... homogenizer, the PandaPLUS 2000, which is ideal for new ... cell disruption . This compact laboratory homogenizer is ... liquid food, food additives and ingredients as well as ...
(Date:1/22/2015)... 22, 2015 Crystal Diagnostics (CDx) Xpress System, ... has received AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing ... collectively referred to as STEC or the “Big-6”) as well ... unit (cfu) per 325 g of raw ground beef and ...
(Date:1/22/2015)... 22, 2015 Selexis SA, a serial ... Cell Banks (RCBs) used for drug discovery to commercial ... will include Next-Generation Sequencing (NGS) data packages. ... biologic manufacturing by ensuring the integrity of the gene, ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... world leader in clinical trial support services, today announced ... located in Austin, TX, is a leader in the ... "True Human" monoclonal antibody into clinical trials. XBiotech,s lead ... being developed to treat diseases such as cancer, atherosclerosis, ...
... ARBOR, Mich., June 2, 2011 Adeona Pharmaceuticals, Inc. ... innovative medicines for serious central nervous system diseases, announced ... clinical study evaluating reaZin along with near-term ... statistical analysis with the Company,s scientific advisors, Adeona intends ...
... June 2, 2011 Sequenom, Inc. (NASDAQ: ... analysis solutions, today announced it and its subsidiary Sequenom ... $30.0 million financing commitment from Silicon Valley Bank’s San ... to support the development and commercialization of new products ...
Cached Biology Technology:C3i Inc to Provide Full-Service Technology Support and Oracle Clinical, Oracle Remote Data Capture Business Process Outsourcing to XBiotech, Inc 2Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy 2Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy 3Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy 4Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy 5Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy 6Sequenom Enters Into New $30.0 Million Credit Facility 2Sequenom Enters Into New $30.0 Million Credit Facility 3Sequenom Enters Into New $30.0 Million Credit Facility 4
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Global Wearable Technologies Market and Applications, Opportunities, ... and Forecast 2014-2020" report to their offering. ... devices that can be worn on the user,s ...
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) has ... Watermarking and Fingerprinting Markets" report to their ... This insight provides an overview of ... Watermarking aims to control and monitor piracy by ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2
... Federal Court of Appeals has overturned an August 2010 ban ... way for broader exploration of how stem cells function and ... of currently incurable diseases. The ruling has been welcomed ... in 2009, and by the nation,s top researchers in the ...
... A gene therapy approach using a protein called CD59, ... age-related macular degeneration (AMD), according to a new in ... Medicine. Led by senior author Rajendra Kumar-Singh, PhD, the ... by a gene therapy approach significantly reduced the uncontrolled ...
... Today, scientists from the California Academy of Sciences will ... in the Philippines, documenting both terrestrial and marine life ... the depths of the sea. They will be joined ... La Salle University, the Philippines National Museum and the ...
Cached Biology News:US Appeals Court opens federal funding for stem cell research 2Gene therapy shows promise against age-related macular degeneration 2California Academy of Sciences launches scientific expedition to the Philippines 2California Academy of Sciences launches scientific expedition to the Philippines 3California Academy of Sciences launches scientific expedition to the Philippines 4California Academy of Sciences launches scientific expedition to the Philippines 5
... GEMINI is Tecan's pipetting software for ... GENESIS Freedom and the GENESIS WORKSTATION instruments ... intuitive software enables the user the simple ... of pipetting scripts. With the powerful scripting ...
Transfection Buffer A & B Set 5 ml each...
...
Intestinal Epithelium Differentiation Environment...
Biology Products: